By Lindsey Rios, PMP, Wayne Bowden, MBA, and Michelle Bousquet, Ph.D.
Every year, tens of thousands of clinical trials are initiated. Every year, thousands of those trials falter, and, if corrective action isn’t taken, some may fail to produce usable data. In an analysis conducted by the Biorasi research team, we discovered that a full third of trials slated to complete within the next year have already passed their predicted completion date1. Given the magnitude of the problem, there is not nearly enough light being shed on this pervasive issue by the industry. In this first white paper in our series, we want to attempt to characterize the scope of the problem facing the drug development industry, and make a case for early, proactive intervention in faltering clinical trials.